

Gi-Ae Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4790216/publications.pdf>

Version: 2024-02-01

28
papers

1,495
citations

516710

16
h-index

642732

23
g-index

28
all docs

28
docs citations

28
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. <i>Gut</i> , 2014, 63, 1325-1332.	12.1	319
2	Association between non-alcoholic fatty liver disease and cancer incidence rate. <i>Journal of Hepatology</i> , 2018, 68, 140-146.	3.7	185
3	High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. <i>Gut</i> , 2018, 67, 945-952.	12.1	176
4	Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1983-1994.	7.3	127
5	Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance. <i>Journal of Hepatology</i> , 2015, 62, 1092-1099.	3.7	114
6	Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging With Gadoteric Acid Detects Additional Lesions and Increases Overall Survival. <i>Gastroenterology</i> , 2015, 148, 1371-1382.	1.3	106
7	Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 320-329.e6.	0.5	75
8	High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 215-226.	3.7	68
9	Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study. <i>Gut and Liver</i> , 2019, 13, 67-76.	2.9	57
10	Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1169-1179.	3.7	50
11	Reappraisal of serum alpha-fetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. <i>Liver International</i> , 2015, 35, 232-239.	3.9	35
12	Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. <i>Gut</i> , 2021, 70, 2172-2182.	12.1	30
13	Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 406-414.	0.4	29
14	Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study. <i>Liver International</i> , 2022, 42, 1027-1036.	3.9	23
15	Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 62, 1076-1084.	3.7	21
16	Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222.	12.1	20
17	Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	17
18	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e264.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. <i>BMC Gastroenterology</i> , 2017, 17, 15.	2.0	11
20	Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B. <i>Yonsei Medical Journal</i> , 2019, 60, 1203.	2.2	10
21	Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7781-7791.	2.8	6
22	Reply to: "The role of NAFLD in extrahepatic malignancies: The importance of ruling out the effect of obesity". <i>Journal of Hepatology</i> , 2018, 68, 1094-1095.	3.7	1
23	Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 576-577.	3.7	1
24	Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1440-1441.	3.7	1
25	Response to: "Prognosis of immune-tolerant phase chronic hepatitis B" by Chu and Liaw. <i>Gut</i> , 2018, 67, 988.2-989.	12.1	0
26	IDDF2018-ABS-0200...Non-linear association between serum hepatitis B virus dna levels and hepatocellular carcinoma risk in treatment-naive, non-cirrhotic chronic hepatitis B patients. , 2018, , .		0
27	IDDF2018-ABS-0150...Risk of hepatocellular cancer and death/transplant between inactive hepatitis b and hbeag-negative chronic hepatitis b with antiviral agents. , 2018, , .		0
28	Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B"authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 763-763.	3.7	0